- Home
- NXE vs ICLR Comparison
NXE vs ICLR Comparison
Compare NXE & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NXE | ICLR |
|---|---|---|
| Founded | 2011 | 1990 |
| Country | Canada | Ireland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 9.3B |
| IPO Year | 2017 | 2001 |
Fundamental Metrics
Financial Performance| Metric | NXE | ICLR |
|---|---|---|
| Price | $12.20 | $116.86 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $178.62 |
| AVG Volume (30 Days) | ★ 5.6M | 1.4M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $75.07 | N/A |
| P/E Ratio | ★ N/A | $12.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.29 | $66.57 |
| 52 Week High | $13.96 | $211.00 |
Technical Indicators
Market Signals| Indicator | NXE | ICLR |
|---|---|---|
| Relative Strength Index (RSI) | 49.63 | 51.67 |
| Support Level | $11.69 | $99.11 |
| Resistance Level | $13.51 | $116.85 |
| Average True Range (ATR) | 0.62 | 6.67 |
| MACD | -0.04 | 0.55 |
| Stochastic Oscillator | 43.22 | 57.79 |
Price Performance
Historical ComparisonAbout NXE Nexgen Energy Ltd.
NexGen Energy Ltd is an exploration and development stage entity engaged in the acquisition, exploration, evaluation, and development of uranium properties in Canada. The Rook I Project is a development-stage uranium project in Canada. The Company also holds a prospective portfolio of uranium exploration projects in the historic eastern Athabasca Basin.
About ICLR ICON plc
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.